Trial comparing treatments for Atrial Fibrillation (AF)
Official title Extended Ablation Versus Pulmonary Vein Isolation to Treat Persistent Atrial Fibrillation
ClinicalTrials.gov ID: NCT07424326
What this study is testing
- What it's testing
- The aim is to determine the effect of extended ablation (pre-specified linear PF/RF lesion set) in addition to PVI in symptomatic persistent AF patients on AF/AT/AFL recurrence. The study is designed as multicenter, randomized trial.
- Time commitment: about 24 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- symptomatic persistent AF
- ≥1 episode of persistent AF in the last 12 months
- signed informed consent
You likely can't join if
- first-manifested AF, paroxysmal AF, long-standing persistent AF, permanent AF
- SR on admission without Class I/III AADs
- AF of secondary cause (e.g. hyperthyroidism)
- any previous LA ablation
- severe valvular disease (mitral valve insufficiency ≥3+, moderate or severe aortic stenosis) or history of valvular surgery or intervention
- left ventricular ejection fraction ≤40%
See the full eligibility criteria
- symptomatic persistent AF
- ≥1 episode of persistent AF in the last 12 months
- signed informed consent
- first-manifested AF, paroxysmal AF, long-standing persistent AF, permanent AF
- SR on admission without Class I/III AADs
- AF of secondary cause (e.g. hyperthyroidism)
- any previous LA ablation
- severe valvular disease (mitral valve insufficiency ≥3+, moderate or severe aortic stenosis) or history of valvular surgery or intervention
- left ventricular ejection fraction ≤40%
- pulmonary hypertension (estimated systolic pulmonary artery pressure ≥40 mm Hg)
- symptomatic coronary artery disease
- pregnancy
- LA anteroposterior diameter ≥55 mm
- body mass index ≥40 kg/m2
- age ≥80 years
- chronic kidney disease stage 3b or higher
- contraindication to anticoagulation
- general contraindications of catheter ablation
- life expectancy \<2 years due to other comorbidities
The study team makes the final eligibility decision.
Where it's taking place
- Olomouc, Czechia
- Prague, Czechia
Compensation & support
This study's listing mentions compensation or reimbursement.
No amount is published here - ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 24 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Olomouc, Czechia; Prague, Czechia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.